Kestra Medical Technologies filings document the public-company disclosures of a Bermuda-incorporated medical technology issuer listed on Nasdaq under KMTS. Its Form 8-K reports have furnished quarterly and annual financial results, revenue guidance, and Regulation FD disclosures tied to the ASSURE WCD and ACE-PAS post-approval study results.
The company’s proxy materials and annual meeting filings cover board elections, independent auditor ratification, shareholder voting results, and equity compensation matters, including the 2025 Employee Stock Purchase Plan. These records also identify governance procedures and formal shareholder actions for the wearable defibrillator and digital health business.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported that director Mary Kay Ladone had two equity-related transactions. On September 9, 2026, she received a grant of 7,217 restricted stock units, each convertible into one common share, scheduled to vest on September 9, 2027, subject to continued service. On September 8, 2026, she sold 3,908 common shares at a weighted average price of $25.1956 per share in a nondiscretionary “sell to cover” transaction to satisfy tax withholding obligations from the vesting and settlement of restricted stock units, with sale prices ranging from $24.91 to $25.43 per share. A prior pro rata distribution had included 17,512 common shares received from West Affum Holdings, L.P., referenced in her holdings.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported the results of its 2026 annual general meeting of shareholders held on September 9, 2026. A total of 55,399,491 common shares were voted in person or by proxy, representing 94.53% of the 58,603,121 shares outstanding and entitled to vote as of July 17, 2026.
Shareholders elected Class II directors Raymond W. Cohen, Kevin Reilly, and Traci S. Umberger to serve until the 2029 annual meeting and until their successors are duly elected and qualified. Shareholders also ratified PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year ending April 30, 2027.
Kestra Medical Technologies, Ltd. (KMTS) stockholder Jeffrey Lawrence Schwartz filed a notice of proposed sale under Rule 144 for 3,890 common shares of KMTS through Merrill Lynch. The shares were acquired on September 4, 2026 via vesting of a restricted stock unit award granted under the issuer’s equity compensation plan.
The proposed sale is tied to an aggregate market value of approximately $97,944.47. KMTS had 58,602,497 common shares outstanding as of the date referenced in the notice, which serves as context for the relative size of this planned disposition.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) received a notice that officer Conor Hanley plans to sell shares of its common stock under Rule 144. The notice covers 5,694 shares of common stock to be sold through Merrill Lynch on NASDAQ with an aggregate value of $143,778.46.
The shares relate to awards that vested on September 4, 2026, which were granted as part of the issuer’s equity compensation plan.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) received a notice that officer Kevin C. Reilly intends to sell up to 2,932 shares of common stock under Rule 144. The proposed sale, through Merrill Lynch on NASDAQ, has an aggregate market value of $73,677.37 based on current data in the notice.
The shares derive from restricted stock unit awards that vested on September 4, 2026 and were granted as part of the company’s equity compensation plan. KMTS had 58,602,497 shares of common stock outstanding as referenced in the notice.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) received a notice that officer Mary Kay Ladone may sell shares of its common stock under Rule 144. The notice covers 3,908 shares of common stock to be sold through Merrill Lynch on NASDAQ, with an indicated aggregate market value of $98,464.49 as of September 8, 2026.
The shares were acquired on September 4, 2026 through the vesting of restricted stock unit awards granted under an issuer equity compensation plan.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported that President and Chief Executive Officer Brian Daniel Webster sold 15,000 Common Shares on August 17, 2026 in an open-market transaction at a weighted average price of $27.4787 per share, with individual sale prices ranging from $26.9200 to $27.7700. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025. Following this sale, Webster directly holds 460,215 Common Shares.
Brian Webster filed a notice to sell 15,000 shares of Kestra Medical Technologies, Ltd. (KMTS) common stock through Merrill Lynch on 08/17/2026, with a proposed aggregate value of $412,180.90. These shares were granted on 07/14/2026 as a Performance Stock Issuance under the issuer’s equity compensation plan. The notice also lists several prior sales between April 15 and August 4, 2026, with individual transactions ranging from 7,857–51,900 shares and $178,531.04–$1,272,585.45 in proceeds.
T. Rowe Price Associates, Inc. reports beneficial ownership of 4,968,900 shares of Kestra Medical Technologies common stock, representing 8.5% of the class as of June 30, 2026. The firm has sole voting power over 4,966,936 shares and sole dispositive power over 4,968,900 shares, with no shared voting or dispositive power. T. Rowe Price Associates states that this report should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.
Kestra Medical Technologies CFO Vaseem Mahboob reported selling a total of 26,287 Common Shares of KMTS on August 7, 2026 in two open-market transactions under a Rule 10b5-1 trading plan adopted November 6, 2025. The reported sales occurred at weighted average prices of $25.8742 and $26.3300 per share, with detailed price ranges disclosed in the footnotes.